Dataset Information

EMD386088 (5 mg/kg) has no effect on latent inhibition shown to both light and noise stimuli.

ABSTRACT: Activation of 5-hydroxytyptamine₆ (5-HT₆) receptors stimulates attentional switching and 5-HT₆ receptor antagonists are putative drugs for psychosis. Latent inhibition (LI) provides a pre-clinical model of attentional switching and 'antipsychotic-like' action and is known to be modulated by 5-hydroxytyptamine. In the present study, LI was shown in a fear conditioning procedure that measured suppression of drinking after conditioning with footshock. In two experiments (each n = 48) it was shown that pre-exposure to both light- and noise-conditioned stimuli reduced conditioned suppression relative to the corresponding non-pre-exposed control. However, counter to prediction, LI was intact after treatment with the 5-HT₆ agonist EMD386088 (5 mg/kg).

SUBMITTER: Cassaday HJ

PROVIDER: S-EPMC6947809 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

EMD386088 (5 mg/kg) has no effect on latent inhibition shown to both light and noise stimuli.

Cassaday Helen Joan HJ Thur Karen Elizabeth KE

Journal of psychopharmacology (Oxford, England) 20191017 1

Activation of 5-hydroxytyptamine6 (5-HT6) receptors stimulates attentional switching and 5-HT6 receptor antagonists are putative drugs for psychosis. Latent inhibition (LI) provides a pre-clinical model of attentional switching and 'antipsychotic-like' action and is known to be modulated by 5-hydroxytyptamine. In the present study, LI was shown in a fear conditioning procedure that measured suppression of drinking after conditioning with footshock. In two experim ...[more]

PMID: 31621457

Dataset Information

EMD386088 (5 mg/kg) has no effect on latent inhibition shown to both light and noise stimuli.

Publications

EMD386088 (5 mg/kg) has no effect on latent inhibition shown to both light and noise stimuli.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Comparative safety and efficacy of 0.6 mg/kg versus 0.9 mg/kg alteplase in acute ischemic stroke: a systematic review and meta-analysis.
| S-EPMC12625435 | biostudies-literature

Comparison of the initial and residual speed of Ixodes scapularis kill on dogs treated with a single dose of Bravecto<sup>®</sup> Chew (25 mg/kg fluralaner) or Simparica TRIO<sup>®</sup> (1.2 mg/kg sarolaner, 24 µg/kg moxidectin, 5 mg/kg pyrantel).
| S-EPMC10683217 | biostudies-literature

HiSNAP trial-a multicentre, randomised, open-label, blinded end point, safety and efficacy trial of conventional (300 mg/kg) versus higher doses of acetylcysteine (450 mg/kg and 600 mg/kg) in patients with paracetamol overdose in the UK: study protocol.
| S-EPMC11977480 | biostudies-literature

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results.
| S-EPMC6879315 | biostudies-literature

ATAC-seq for LuCaP145.2 tumors treated with 50 mg/kg JQ1 or 10 mg/kg AZD5153 for 7 days
2024-10-23 | GSE265757 | GEO

Transcription profiling of total of rat liver samples treated with 300 mg/kg/day myclobutanil, 300 mg/kg/day propiconazole, and 175 mg/kg/day triadimefon
2008-04-08 | E-GEOD-10409 | biostudies-arrayexpress

Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire.
| S-EPMC6199801 | biostudies-literature

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma.
| S-EPMC7279645 | biostudies-literature